on BIOMERIEUX (EPA:BIM)
BioMérieux Reports Strong First-Quarter 2025 Growth
In the first quarter of 2025, bioMérieux saw a 12.7% organic sales increase, marking its fifth consecutive quarter with double-digit growth. The GO•28 strategic plan's growth drivers contributed significantly, with the BIOFIRE® respiratory panels experiencing a 21% increase. The company installed 1,400 new SPOTFIRE® instruments, leading to a 166% increase in sales.
The company maintains its 2025 sales guidance of at least 7% growth. Despite a volatile environment and an anticipated negative currency impact of €35m-€40m on the annual CEBIT, bioMérieux is confident in achieving 10% CEBIT growth compared to 2024.
The first quarter sales analysis by application reveals growth in clinical and industrial applications, while regionally, North America spearheaded growth with a 19% increase.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOMERIEUX news